Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Epithelium-on photorefractive intrastromal cross-linking (PiXL) with supplemental oxygen for low hyperopic treatment in post-refractive surgery Asian eyes

Poster Details

First Author: J.Theng SINGAPORE

Co Author(s):    W. Lim   M. Puah   C. Chua   F. Gasper   F. Khoo        

Abstract Details


To report the 6 months results of low hyperopic correction with epithelium-on PiXL with supplementary oxygen for post-refractive surgery eyes


Eagle Eye Centre, Singapore


PiXL procedure was conducted on post-refractive surgery patients for low hyperopic treatment. The PiXL treatment were designed to deliver a 9mm annulus ring of 1mm thickness (for hyperopic treatment) of UVA light with supplemental oxygen at a rate of 2mL/minute. Clinical evaluation included safety (BCVA, ECC, anterior ocular health) and efficacy (UCVA, manifest refraction, keratometric parameters) checks. 2 dominant eyes were treated for distance vision and 5 non dominant eyes were treated for near vision. Questionnaires were conducted to analyse the patient’s subjective experience with the procedure during their 1st and 6th months post procedure review.


7 ametropic eyes (median 0.00DS; range -0.63 to +0.75D) of 6 subjects (mean age 50.5 years old; range 45 to 59 years old) were treated. 1-month data revealed a median refractive change of -0.50D (range -1.50 to -0.13D) and median Kmean steepening of 0.40D (range 0.2 to 0.8D). Median UDVA improved from 0.20 logMAR (range 0.16 to 0.24) pre-PiXL to -0.05 logMAR (range -0.06 to -0.04) at 1 month while median UNVA improved from N18 (range N5 to N24) pre-PiXL to N5 (range N5 to N18) at 1 month.


Early results of hyperopic PiXL with oxygen are encouraging for visual refinement in post-refractive surgery eyes with noticeable improvement in near vision. However, longer-term data to assess the sustainability of the treatment and larger studies are still required.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing